Unknown Long-Term Safety Profile: A short plasma half-life of under 30 minutes in rats and dogs, alongside low bioavailability after intramuscular administration, raises critical questions about what occurs with higher, repeated, or long-term exposures in humans
The peptides are available for research and laboratory purposes only
Compounded medications are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
A synthetic peptide appears to directly disrupt the destructive inflammation that occurs in nephritis, enabling the kidneys to better recover and maintain their important functions, investigators report